Get started
Author

Ali Kalem

Observed names: A. Kalem, Ali̇ Kalem, Kalem, Ali
ORCID: 0009-0001-0937-0468
Observed ORCID: 0009-0001-0937-0468
OpenAlex ID: A5090843246
New inflammatory markers in early rheumatoid arthritis
2016 · O. Zengin, M. E. Onder, et al. · Zeitschrift für Rheumatologie · 49
Isotretinoin-induced Spondyloarthropathy-related Symptoms: A Prospective Study
2015 · Samet Alkan, Nuriye Kayiran, et al. · The Journal of Rheumatology · 45
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
2025 · Sedat Yıldırım, Tugba Başoğlu, et al. · BMC Cancer · 2
PDF
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · Medicina · 1
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study
2026 · Taha Koray Sahin, Fatih Kemik, et al. · Therapeutic Advances in Medical Oncology · 1
Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)
2025 · Ali Kalem, Tulay Kus, et al. · Journal of Clinical Medicine · 1
PDF
Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · BMC Cancer
Comparison of 24 Versus 46-Hour 5-FU Infusion Durations in the Perioperative FLOT Therapy for Gastric Cancer
2026 · Savas Gokcek, Pervin Can Sancı, et al. · Medicina
Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study ( TOG / GI ‐ SAFRADJU ‐2501)
2026 · Erman Akkus, Mehmet Kayaalp, et al. · International Journal of Cancer
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
2026 · Mustafa Seyyar, Ali Kalem, et al. · Current Oncology
PDF
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study
2026 · Anıl Karakayalı, Mustafa Seyyar, et al. · Medicina
Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure
2026 · Fatih Kemik, Taha Koray Şahin, et al. · The Breast
Real-World Outcomes of Irinotecan–Bevacizumab Therapy in Recurrent Brain Tumors: A Retrospective Cohort Study
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)
2026 · Erman Akkus, Mehmet Kayaalp, et al. · JCO Global Oncology
Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer
2026 · F. Kemik, T. K. Sahin, et al. · Clinical Cancer Research
Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study
2026 · T. Sahin, F. Kemik, et al. · Clinical Cancer Research
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group
2026 · Salih Tunbekici, Hamit Bal, et al. · Clinical & Translational Oncology
Meme Kanseri
2026 · Semra Taş, Ali Alper Solmaz, et al. · Akademisyen Kitabevi eBooks
PDF
Kalıtsal Meme Kanser Sendromları
2026 · Ali Kalem · Akademisyen Kitabevi eBooks
Her2 Pozitif Metastatik Meme Kanserli Hastalarda Trastuzumab Deruxtecan’in Gerçek Yaşam Verileri: Türk Onkoloji Grubu Çok Merkezli Çalişmasi
2025 · Oruç, Ahmet, Şahin, Taha Koray, et al. · Kocaeli Üniversitesi - AVESİS
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)
2025 · Ali Kalem, Tulay Kus, et al. · Cancers
PDF
FOLFIRINOX: The best adjuvant treatment for ampullary adenocarcinoma?
2025 · Ali̇ Kalem, Tulay Kus, et al. · Journal of Clinical Oncology
Comparison of frontline FOLFIRINOX with fluorouracil-based and gemcitabine-basedchemotherapies in metastatic ampullary adenocarcinoma: A multicenter cohort study.
2025 · Ali̇ Kalem, Tulay Kus, et al. · Journal of Clinical Oncology
PDF
Works count: 23
Citation count: 99
H-index: 2
I10-index: 2
Year
Topic
Type